Inclusion Criteria for All Subjects:

1. Male and Female between 18 and 75 years old

2. BMI 17.5 to 40.0 kg/m^2 and a total body weight >50 kg (110 lb) 3 .Female subjects
must either be not of childbearing potential or if they are a woman of childbearing
potential, they are only eligible if they and any non-sterile, male sexual partners
agree to use highly effective contraceptive therapy

4. Female subjects must have a negative serum pregnancy test at screening

Inclusion Criteria for Subjects with Normal Hepatic Function:

1. Good general health as defined by no clinically relevant abnormalities identified by
Medical History and a vital signs and 12-lead electrocardiogram (ECG) assessment

2. Subjects must fit the demographic-matching criteria including body weight, age, and
to the extent possible, gender

3. Normal hepatic function with no known or suspected hepatic impairment

Inclusion Criteria for Subjects with Impaired Hepatic Function:

1. Subject satisfies the criteria for Class B of the Child-Pugh classification (Child
Pugh Scores 7-9 points) within 28 days of study drug administration

2. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary
to any acute ongoing hepatocellular process) documented by medical history, physical
examination, liver biopsy, hepatic ultrasound, Fibroscan, computerized tomography
scan, or magnetic resonance imaging (MRI)

3. Stable hepatic impairment for at least 3 months prior to screening or second
screening visit to demonstrate stability

4. Stable concomitant medications for the management of an individual subject's medical
history for at least 28 days prior to screening

5. Subjects must have a 12-lead ECG and vital signs assessment that meet the protocol
criteria

Exclusion Criteria for All Subjects:

1. Subjects with any current or previous illness that, in the opinion of the
Investigator, might confound the results of the study or pose an additional risk in
administering study drug to the subject or that could prevent, limit, or confound
the protocol specified assessments or study results' interpretation

2. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de
Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history
or clinical evidence at screening of significant or unstable cardiac disease etc.

3. Subjects with a history of clinically significant drug allergy

4. Subjects with a recent (within 1 year of randomization) history or current evidence
of drug abuse or recreational drug use

5. Excessive use of alcohol defined as regular consumption of ≥14 units/ week for women
and ≥21 units/week for men

6. Unwilling to abstain from alcohol use for 48 hours prior to start of the study
through end of study follow up

7. Subjects with Hepatitis A, B, C, E or HIV-1/HIV-2 infection or acute infections such
as SARS- CoV-2 infection. Subejcts with Hepatitis B infection may be eligible for
moderate impairment cohort provided provided they met stable treatment criteria.
Subjects with HIV infection may be eligible for moderate impairment cohort provided
they met stable treatment criteria.

Exclusion Criteria for Subjects with Normal Hepatic Function:

1. Estimated creatinine clearance <60 mL/min/1.73 m2 at screening, calculated by the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula] - Unless
otherwise instructed by the Study Review Committee (SRC), CKD-EPI should not be
corrected for subjects of African ancestry

2. Bilirubin (total, direct) >1.2× upper limit of normal (ULN) (unless Gilbert's is
suspected)

3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level > 1.2×ULN

4. Grade ≥1 Hemoglobin

Exclusion Criteria for Subjects with Impaired Hepatic Function:

1. Subjects with advanced ascites (Grade 3)

2. Subjects with refractory encephalopathy as judged by the investigator.

3. Subjects with esophageal variceal bleeding within the past 6 months prior to
screening.

4. Subjects with Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement.

5. Estimated creatinine clearance <60 mL/min/1.73 m2 at screening, calculated by the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula] - Unless
otherwise instructed by the SRC, CKD-EPI should not be corrected for subjects of
African ancestry

6. ALT or AST level ≥5×ULN

7. Serum sodium ≤125 mmol/L

8. Platelets <50×10^9/L

9. Grade ≥2 Hemoglobin